Chemo-resistant tumors targeted by BU School of Medicine researcher

November 02, 2015

(Boston)--Rachel Flynn, PhD, assistant professor of pharmacology and medicine at Boston University School of Medicine (BUSM), is the recipient of an Elsa U. Pardee award for approximately $148,000 for "Targeting the Alternative Lengthening of Telomeres (ALT) Pathway in cancer." This pathway is frequently reactivated in aggressive cancers such as osteosarcoma and glioblastoma, which are often resistant to standard chemotherapy.

Flynn's lab uses a combination of biochemical and cell biological approaches to study mechanisms of telomere maintenance.The telomere is a repetitive DNA sequence that caps the ends of each human chromosome and acts as a barrier, protecting the genome. Each time a cell divides, a portion of this barrier is lost and over time genetic information becomes susceptible to degradation and/or damage.

To avoid this type of damage critically short telomeres send a signal to the cell to induce either growth arrest or cell death. Cancer cells, however, have evolved mechanisms to overcome progressive telomere shortening and bypass this growth arrest. One mechanism promoting telomere elongation is the ALT pathway.

Flynn has recently identified a small molecule that selectively kills ALT-positive cancer cells. "This grant will further validate the use of this small molecule and if successful, has the potential to redefine the therapeutic approach to some of the most deadly forms of human cancer. We are grateful to the Elsa U. Pardee Foundation for their generosity," she added.
-end-
The Elsa U. Pardee Foundation was established in 1944 under the terms of the will of Mrs. Elsa U. Pardee, whose life was taken by cancer on October 2, 1944. Mrs. Pardee provided a $1 million trust fund "for the promotion of the control and cure of cancer." She directed that this bequest be used to support research in the field of cancer and to provide for others the advantages of new knowledge and techniques for the treatment of this related group of disabling and frequently lethal diseases.

Since 1944, this family-run foundation has proudly granted over $125 million to support two key areas including research programs directed toward discovering new approaches for cancer treatment and cure and financial support for cancer treatment.

Boston University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.